WO2021203701A1 - Application du sofosbuvir dans la préparation d'un médicament destiné à prévenir et à traiter les coronavirus - Google Patents
Application du sofosbuvir dans la préparation d'un médicament destiné à prévenir et à traiter les coronavirus Download PDFInfo
- Publication number
- WO2021203701A1 WO2021203701A1 PCT/CN2020/129175 CN2020129175W WO2021203701A1 WO 2021203701 A1 WO2021203701 A1 WO 2021203701A1 CN 2020129175 W CN2020129175 W CN 2020129175W WO 2021203701 A1 WO2021203701 A1 WO 2021203701A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coronavirus
- cov
- sofosbuvir
- preparation
- sars
- Prior art date
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title claims abstract description 30
- 229960002063 sofosbuvir Drugs 0.000 title claims abstract description 30
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 241000315672 SARS coronavirus Species 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 150000002148 esters Chemical class 0.000 claims abstract description 12
- 229940002612 prodrug Drugs 0.000 claims abstract description 12
- 239000000651 prodrug Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 150000001408 amides Chemical class 0.000 claims abstract description 11
- 244000309467 Human Coronavirus Species 0.000 claims abstract description 8
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims description 17
- -1 acemonam Chemical compound 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000000645 desinfectant Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 4
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000002923 oximes Chemical class 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- IWKXBHQELWQLHF-CAPFRKAQSA-N (ne)-n-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=N\O)\C1=CC=CC=C1 IWKXBHQELWQLHF-CAPFRKAQSA-N 0.000 claims description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
- LFFGEYHTAJZONR-UHFFFAOYSA-N 1-[(4-methoxyphenoxy)methyl]-3,4-dihydroisoquinoline;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1OCC1=NCCC2=CC=CC=C12 LFFGEYHTAJZONR-UHFFFAOYSA-N 0.000 claims description 2
- KCURWTAZOZXKSJ-JBMRGDGGSA-N 4-amino-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydron;chloride Chemical compound Cl.O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 KCURWTAZOZXKSJ-JBMRGDGGSA-N 0.000 claims description 2
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 claims description 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 2
- 241001109669 Human coronavirus HKU1 Species 0.000 claims description 2
- 241001428935 Human coronavirus OC43 Species 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 2
- IRHXGOXEBNJUSN-YOXDLBRISA-N Saquinavir mesylate Chemical compound CS(O)(=O)=O.C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 IRHXGOXEBNJUSN-YOXDLBRISA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 claims description 2
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 2
- UDMBCSSLTHHNCD-UHTZMRCNSA-N [(2r,3s,4s,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O UDMBCSSLTHHNCD-UHTZMRCNSA-N 0.000 claims description 2
- 229960004748 abacavir Drugs 0.000 claims description 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- 229940008235 acyclovir sodium Drugs 0.000 claims description 2
- 229960001997 adefovir Drugs 0.000 claims description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 2
- 229950004424 alovudine Drugs 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229960000724 cidofovir Drugs 0.000 claims description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 2
- 229960002656 didanosine Drugs 0.000 claims description 2
- QGXLVXZRPRRCRP-MMGZGRSYSA-L disodium;[(2r,3s,4s,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H]1O QGXLVXZRPRRCRP-MMGZGRSYSA-L 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229950008161 enviroxime Drugs 0.000 claims description 2
- 229960004396 famciclovir Drugs 0.000 claims description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002963 ganciclovir Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 2
- 229960001936 indinavir Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 229960001627 lamivudine Drugs 0.000 claims description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229960004525 lopinavir Drugs 0.000 claims description 2
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 claims description 2
- 229960000689 nevirapine Drugs 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
- 229960000888 rimantadine Drugs 0.000 claims description 2
- 229960000311 ritonavir Drugs 0.000 claims description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 2
- 229960003542 saquinavir mesylate Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- KNBQMQYQYHZXSX-UHFFFAOYSA-M sodium;2-phosphonoacetate Chemical compound [Na+].OP(O)(=O)CC([O-])=O KNBQMQYQYHZXSX-UHFFFAOYSA-M 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229960004556 tenofovir Drugs 0.000 claims description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 2
- 229960003962 trifluridine Drugs 0.000 claims description 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 2
- 229960003636 vidarabine Drugs 0.000 claims description 2
- 229960000523 zalcitabine Drugs 0.000 claims description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 2
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 claims 2
- FRFMOVPIHHDDPP-UHFFFAOYSA-N 1-ethoxybutan-2-one Chemical compound CCOCC(=O)CC FRFMOVPIHHDDPP-UHFFFAOYSA-N 0.000 claims 1
- GCQYYIHYQMVWLT-HQNLTJAPSA-N Sorivudine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 GCQYYIHYQMVWLT-HQNLTJAPSA-N 0.000 claims 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 1
- 229960005102 foscarnet Drugs 0.000 claims 1
- 229960002687 ganciclovir sodium Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229950009279 sorivudine Drugs 0.000 claims 1
- 229960001203 stavudine Drugs 0.000 claims 1
- 229940064636 valacyclovir hydrochloride Drugs 0.000 claims 1
- 208000025721 COVID-19 Diseases 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 206010035664 Pneumonia Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 229940126656 GS-4224 Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KCHIOGFOPPOUJC-UHFFFAOYSA-N (methylpyridazine piperidine ethyloxyphenyl)ethylacetate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCC1CCN(C=2N=NC(C)=CC=2)CC1 KCHIOGFOPPOUJC-UHFFFAOYSA-N 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000112287 Bat coronavirus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- 101710147732 Small envelope protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- MEPNHSOMXMALDZ-UHFFFAOYSA-N delavirdine mesylate Chemical compound CS(O)(=O)=O.CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 MEPNHSOMXMALDZ-UHFFFAOYSA-N 0.000 description 1
- 229960000475 delavirdine mesylate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229960000848 foscarnet sodium Drugs 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 108010028403 hemagglutinin esterase Proteins 0.000 description 1
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 229950011136 pirodavir Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the African green monkey kidney cells (VeroE6) were inoculated into 96-well plates at 3 ⁇ 10 5 cells/well, and placed in the minimum Eagle's medium (MEM; GibcoInvitrogen) containing 10% fetal bovine serum (FBS; GibcoInvitrogen). Incubate at 37°C with 5% CO 2 until the monolayer grows up. A 100-fold dilution of the novel coronavirus clinical isolates of the novel coronavirus pneumonia was inoculated into a 96-well plate full of monolayer cells, and cultured at 37°C and 5% CO 2 for two days (including the normal control group).
- MEM minimum Eagle's medium
- FBS fetal bovine serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne l'application du sofosbuvir dans la préparation d'un médicament destiné à prévenir et traiter les coronavirus. L'invention concerne en particulier une application du sofosbuvir ou d'un isotope, d'un stéréoisomère, d'un mélange de stéréoisomères, d'un tautomère, d'un ester, d'un amide, d'un promédicament ou d'un sel de qualité pharmaceutique de celui-ci dans la préparation d'un médicament destiné à prévenir et/ou traiter des maladies provoquées par un coronavirus. Ces coronavirus sont les nouveaux coronavirus SARS-Cov-2, SARS-Cov, HCoV 229E, NL63, OC43, HKU1 et MERS-Cov. La concentration efficace moyenne de sofosbuvir contre un nouveau coronavirus à l'origine de la Covid-19 est égale à 1,12 μΜ, la toxicité est faible, et une bonne fenêtre de traitement est ainsi fournie.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010266185.6A CN111467363A (zh) | 2020-04-07 | 2020-04-07 | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 |
| CN202010266185.6 | 2020-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021203701A1 true WO2021203701A1 (fr) | 2021-10-14 |
Family
ID=71750112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/129175 WO2021203701A1 (fr) | 2020-04-07 | 2020-11-16 | Application du sofosbuvir dans la préparation d'un médicament destiné à prévenir et à traiter les coronavirus |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111467363A (fr) |
| WO (1) | WO2021203701A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021155119A2 (fr) * | 2020-01-29 | 2021-08-05 | The Trustees Of Columbia University In The City Of New York | Agents thérapeutiques contre la covid-19 |
| CN111467363A (zh) * | 2020-04-07 | 2020-07-31 | 中国科学院深圳先进技术研究院 | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 |
| CN112237584B (zh) * | 2020-08-21 | 2021-10-01 | 中国医学科学院医药生物技术研究所 | 化合物预防和/或治疗冠状病毒感染所致疾病的用途 |
| WO2022053164A1 (fr) * | 2020-09-14 | 2022-03-17 | Hc Pharma Ag | Combinaison antivirale pour le traitement d'une infection à la covid-19 |
| WO2022088037A1 (fr) * | 2020-10-30 | 2022-05-05 | 中国科学院深圳先进技术研究院 | Application du sirtinol dans la préparation d'un médicament destiné à prévenir et à traiter un coronavirus |
| WO2022088038A1 (fr) * | 2020-10-30 | 2022-05-05 | 中国科学院深圳先进技术研究院 | Application de cay10603 dans la préparation de médicaments pour la prévention et le traitement de maladies liées aux coronavirus |
| CN112661801A (zh) * | 2020-12-18 | 2021-04-16 | 成都阿奇生物医药科技有限公司 | 一种核苷类似物及其氘代物及其制备方法和用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101918425A (zh) * | 2007-03-30 | 2010-12-15 | 法莫赛特股份有限公司 | 核苷氨基磷酸酯前药 |
| CN104327137A (zh) * | 2014-11-07 | 2015-02-04 | 王彩琴 | 一种氘代索菲布韦及其用途 |
| CN105705511A (zh) * | 2013-04-12 | 2016-06-22 | 艾其林医药公司 | 用于治疗hcv的氘化核苷前药 |
| CN109843900A (zh) * | 2016-08-19 | 2019-06-04 | 桑多斯股份公司 | 治疗丙型肝炎的索非布韦衍生物 |
| CN109862884A (zh) * | 2016-08-12 | 2019-06-07 | 桑多斯股份公司 | 包含无定形索非布韦的固体药物组合物 |
| CN111467363A (zh) * | 2020-04-07 | 2020-07-31 | 中国科学院深圳先进技术研究院 | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 |
-
2020
- 2020-04-07 CN CN202010266185.6A patent/CN111467363A/zh active Pending
- 2020-11-16 WO PCT/CN2020/129175 patent/WO2021203701A1/fr active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101918425A (zh) * | 2007-03-30 | 2010-12-15 | 法莫赛特股份有限公司 | 核苷氨基磷酸酯前药 |
| CN105705511A (zh) * | 2013-04-12 | 2016-06-22 | 艾其林医药公司 | 用于治疗hcv的氘化核苷前药 |
| CN104327137A (zh) * | 2014-11-07 | 2015-02-04 | 王彩琴 | 一种氘代索菲布韦及其用途 |
| CN109862884A (zh) * | 2016-08-12 | 2019-06-07 | 桑多斯股份公司 | 包含无定形索非布韦的固体药物组合物 |
| CN109843900A (zh) * | 2016-08-19 | 2019-06-04 | 桑多斯股份公司 | 治疗丙型肝炎的索非布韦衍生物 |
| CN111467363A (zh) * | 2020-04-07 | 2020-07-31 | 中国科学院深圳先进技术研究院 | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 |
Non-Patent Citations (3)
| Title |
|---|
| CHIEN MINCHEN, ANDERSON THOMAS K., JOCKUSCH STEFFEN, TAO CHUANJUAN, KUMAR SHIV, LI XIAOXU, RUSSO JAMES J., KIRCHDOERFER ROBERT N.,: "Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase", BIORXIV, 20 March 2020 (2020-03-20), XP055841078, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239050/pdf/nihpp-2020.03.18.997585.pdf> [retrieved on 20210914], DOI: 10.1101/2020.03.18.997585 * |
| ELFIKY ABDO A.: "Anti-HCV, Nucleotide Inhibitors, Repurposing against COVID-19", LIFE SCIENCES, vol. 248, 28 February 2020 (2020-02-28), XP086095279, DOI: 10.1016/j.lfs.2020.117477 * |
| MIN JUNG SUN, KIM GEON-WOO, KWON SUNOH, JIN YOUNG-HEE: "A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus RNA-Dependent RNA Polymerase Activity", JOURNAL OF CLINICAL MEDICINE, vol. 9, no. 8, pages 2399, XP055857169, DOI: 10.3390/jcm9082399 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111467363A (zh) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021203701A1 (fr) | Application du sofosbuvir dans la préparation d'un médicament destiné à prévenir et à traiter les coronavirus | |
| WO2021203703A1 (fr) | Utilisation d'acide carglumique dans la préparation de médicaments pour la prévention et le traitement de coronavirus | |
| WO2021203704A1 (fr) | Utilisation de bacitracine a dans la préparation de médicaments pour la prévention et le traitement de coronavirus | |
| WO2021203706A1 (fr) | Utilisation de foscarnet sodium dans la préparation de médicaments pour la prévention ou le traitement de coronavirus | |
| WO2021203702A1 (fr) | Utilisation d'acide pyroglutamique dans la préparation de médicaments pour la prévention et le traitement du nouveau coronavirus responsable de la pneumonie à nouveau coronavirus | |
| KR20190112051A (ko) | 인플루엔자의 치료 방법 | |
| Faisal et al. | Alkaloids as potential antivirals. A comprehensive review | |
| KR20180124970A (ko) | 바이러스 감염을 치료하기 위한 티아졸리드 화합물 | |
| Dinda et al. | Some natural compounds and their analogues having potent anti-SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19 | |
| Upadhayay et al. | Frequently used allopathic and traditional medicine for COVID-19 treatment and feasibility of their integration | |
| WO2021253338A1 (fr) | Utilisation de romidepsine dans la prévention et le traitement de maladies liées au coronavirus | |
| TWI605822B (zh) | 酪梨萃取物、ａｖｏｃａｄｅｎｏｌ Ｂ及（２Ｒ，４Ｒ）－１，２，４－三羥基十七碳－１６－炔的用途，以及包含酪梨萃取物之保健食品 | |
| WO2022088037A1 (fr) | Application du sirtinol dans la préparation d'un médicament destiné à prévenir et à traiter un coronavirus | |
| WO2022088047A1 (fr) | Application de itf2357 dans la préparation d'un médicament destiné à prévenir et à traiter les coronavirus | |
| WO2008017264A1 (fr) | Composition pharmaceutique comprenant des donneurs de méthyle ou des promoteurs de donneur de méthyle et des composés antiviraux | |
| CN113813366A (zh) | 罗米地辛在制备预防和治疗抗新冠肺炎新型冠状病毒的药物中的应用 | |
| Khushboo et al. | Pathophysiology of SARS-CoV2 Mediated Depression, Therapeutics, and Consequences: A Comprehensive Narrative | |
| WO2022088038A1 (fr) | Application de cay10603 dans la préparation de médicaments pour la prévention et le traitement de maladies liées aux coronavirus | |
| WO2022088025A1 (fr) | Application de panobinostat dans la préparation d'un médicament pour la prévention et le traitement du coronavirus | |
| CN111568900A (zh) | 吲哚美辛在抗冠状病毒感染中的应用 | |
| CN113908256B (zh) | Lancl1蛋白在制备抗病毒药物中的应用 | |
| US20230226056A1 (en) | Compatible solutes for preventing or treating sars-cov-2 infections | |
| WO2022228581A1 (fr) | Application de sorbitol 1,5-déshydraté dans la préparation de médicaments pour le traitement et la prévention de maladies provoquées par le virus du sars-cov-2 | |
| WO2022237145A1 (fr) | Utilisation de composition de médecine chinoise traditionnelle dans la préparation d'un médicament permettant de résister à un nouveau coronavirus à mutation d614g dans la protéine s | |
| CN114432305A (zh) | Cay10603在制备预防和治疗冠状病毒的药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20930578 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20930578 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20930578 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 05/07/2023) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20930578 Country of ref document: EP Kind code of ref document: A1 |